University of Pennsylvania Patient-derived Xenograft Development and Trials Center

宾夕法尼亚大学患者来源的异种移植开发和试验中心

基本信息

  • 批准号:
    10733232
  • 负责人:
  • 金额:
    $ 6.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-05 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Summary: The goal of the Administrative Core of the University of Pennsylvania PDX Development and Trials Center is primarily to facilitate innovative translational science that will accelerate the application of new discoveries to the clinic for cancer patients. This will be achieved through a combination of enhancing both the development of unique PDX models at UPENN and through facilitating interaction with the PDXNet. The Administrative Core will be responsible to make sure that the UP-PDTC acts effectively as a research unit of PDXNet. The primary responsibilities of the Administrative Core are to provide scientific leadership, administrative services, and financial oversight, as well as to function as a communication hub for all UP-PDTC-related activities. The Administrative Core will support investigators and personnel in Projects 1-2, the PDX Core, the Pilot Projects and Trans-Network Core, and the Biostatistical Core. The Administrative Core will arrange at least annual meetings of the SAB of the UP-PDTC. Of note, the Administrative Core coordinates all efforts in support of diversity, equity, and inclusion, including ensuring and facilitating wide representation of all minority groups in the tissue banks and PDX models developed by the UP-PDTC. The Administrative Core provides each of these groups with centralized organization and support for their activities, and helps each group stay informed about activities, meetings, opportunities, and other information pertinent to the UP-PDTC. The Administrative Core will be responsible for communication with PDXNet personnel (PDXNet Steering Committee) as well as NCI personnel and will provide support for all collaborations. In particular, the Administrative Core will facilitate interactions between UP-PDTC personnel and the PDXNet Data Commons and Administrative Center. Continuity of support provided by the staff will result in efficient and effective administration for the UP-PDTC.
总结: 宾夕法尼亚大学PDX开发和试验中心的行政核心的目标是 主要是为了促进创新的转化科学,这将加速新发现的应用, 为癌症患者开设的诊所这将通过加强发展和 独特的PDX模型在宾夕法尼亚大学,并通过促进与PDXNet的互动。行政 核心将负责确保UP-PDTC有效地作为PDXNet的研究单位。的 行政核心的主要职责是提供科学领导、行政服务, 和财务监督,以及作为所有UP-PDTC相关活动的通信枢纽。的 行政核心将支持项目1-2、PDX核心、试点项目 和跨网络核心,以及生物统计核心。行政核心将至少每年安排 UP-PDTC的SAB会议。值得注意的是,行政核心协调所有支持下列活动的努力: 多样性、公平和包容性,包括确保和促进所有少数群体的广泛代表性, UP-PDTC开发的组织库和PDX模型。行政核心提供以下各项 这些团体有集中的组织和支持他们的活动,并帮助每个团体保持知情 关于活动,会议,机会和其他与UP-PDTC相关的信息。行政 核心将负责与PDXNet人员(PDXNet指导委员会)沟通,以及 NCI人员,并将为所有合作提供支持。特别是,行政核心将促进 UP-PDTC人员与PDXNet数据共享和管理中心之间的互动。 工作人员提供的持续支持将使UP-PDTC的管理效率和效力提高。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN CARROLL其他文献

MARTIN CARROLL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN CARROLL', 18)}}的其他基金

University of Pennsylvania Patient-derived Xenograft Development and Trials Center
宾夕法尼亚大学患者来源的异种移植开发和试验中心
  • 批准号:
    10733231
  • 财政年份:
    2023
  • 资助金额:
    $ 6.84万
  • 项目类别:
Acute myeloid leukemia (AML) Research Project
急性髓系白血病(AML)研究项目
  • 批准号:
    10733236
  • 财政年份:
    2023
  • 资助金额:
    $ 6.84万
  • 项目类别:
Pathologic Signaling Pathways in AML Cells
AML 细胞的病理信号通路
  • 批准号:
    10341044
  • 财政年份:
    2021
  • 资助金额:
    $ 6.84万
  • 项目类别:
Pathologic Signaling Pathways in AML Cells
AML 细胞中的病理信号通路
  • 批准号:
    10553601
  • 财政年份:
    2021
  • 资助金额:
    $ 6.84万
  • 项目类别:
Pathologic Signaling Pathways in AML Cells
AML 细胞中的病理信号通路
  • 批准号:
    10010684
  • 财政年份:
    2021
  • 资助金额:
    $ 6.84万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    9114538
  • 财政年份:
    2015
  • 资助金额:
    $ 6.84万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    9295847
  • 财政年份:
    2015
  • 资助金额:
    $ 6.84万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    8946188
  • 财政年份:
    2015
  • 资助金额:
    $ 6.84万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    9512555
  • 财政年份:
    2015
  • 资助金额:
    $ 6.84万
  • 项目类别:
(PDQ5)Integrated Genetic and Epigenetic Prognostication for Acute Myeloid Leukemi
(PDQ5)急性髓性白血病的综合遗传和表观遗传预测
  • 批准号:
    8687082
  • 财政年份:
    2014
  • 资助金额:
    $ 6.84万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 6.84万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 6.84万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 6.84万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 6.84万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 6.84万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 6.84万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 6.84万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 6.84万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 6.84万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 6.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了